Safety results of a phase III trial evaluating ADT plus docetaxel versus ADT alone in hormone-naive metastatic prostate cancer patients (GETUG-AFU 15/0403)

被引：0
|
作者：
Latorzeff, I.
Esterni, B.
Habibian, M.
Delplanque, G.
Theodore, C.
Baciuchka, M.
Dauba, J.
Laguerre, B.
Krakowski, I.
Gravis, G.
机构：
[1] Clin Pasteur, Toulouse, France
[2] Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France
[3] Fed Natl Ctr Lutte Canc, Paris, France
[4] Grp Hosp St Joseph, Paris, France
[5] Hop Foch, Suresnes, France
[6] Ctr Hosp Timone, Marseille, France
[7] Hop Layne, Mt De Marsan, France
[8] Ctr Eugene Marquis, Rennes, France
[9] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[10] INSERM, Dept Med Oncol, Inst Paoli Calmettes, UMR 891, F-13258 Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4681
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4681
引用
收藏
页数：1
相关论文
共 50 条
  • [31] UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC).
    Azad, Arun
    Dhiantravan, Nattakorn
    Emmett, Louise
    Joshua, Anthony M.
    Vela, Ian
    Pattison, David A.
    Francis, Roslyn J.
    Williams, Scott
    Sandhu, Shahneen Kaur
    Davis, Ian D.
    Neha, Nitika
    Bressel, Mathias
    Murphy, Declan G.
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [32] Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT plus Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry
    Francini, E.
    Yip, S.
    Ahmed, N. S.
    Li, H.
    Ardolino, L.
    Evan, C. P.
    Kaymakcalan, M.
    Shaw, G. K.
    Kantoff, P.
    Taplin, M. E.
    Alimohamed, N.
    Joshua, A. M.
    Heng, D. Y. C.
    Sweeney, C. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Darolutamide (DARO) in combination with androgendeprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study
    Wang, S.
    Fu, C.
    Li, Y.
    Xing, J.
    Zhou, L.
    Yang, Y.
    Wang, H.
    Smith, M. R.
    Tombal, B.
    Hussain, M.
    Niu, Y.
    Cai, L.
    Liu, Q.
    Littleton, N.
    Li, R.
    Ye, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1572 - S1572
  • [34] Weekly paclitaxel versus ADT alone in localized high-risk prostate cancer: Results of a single-institution phase II trial
    Saldana, Carolina
    Salomon, Laurent
    Rousseau, Benoit
    Chaubet-Houdu, Marie
    Joly, Charlotte
    Ploussard, Guillaume
    Allory, Yves
    Tournigand, Christophe
    de la Taille, Alexandre
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [35] Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.
    Francini, Edoardo
    Gray, Kathryn P.
    Evan, Carolyn
    Kaymakcalan, Marina D.
    Shaw, Grace Katherine
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Gemcitabine plus docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: a review of the results of a European Phase III trial
    Chan, S
    EJC SUPPLEMENTS, 2005, 3 (05): : 17 - 21
  • [37] SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
    Agarwal, Neeraj
    Tangen, Catherine
    Hussain, Maha H. A.
    Gupta, Shilpa
    Plets, Melissa
    Lara, Primo
    Harzstark, Andrea
    Twardowski, Przemyslaw
    Paller, Channing Judith
    Zylla, Dylan M.
    Zibelman, Matthew R.
    Levine, Ellis Glenn
    Roth, Bruce J.
    Goldkorn, Amir
    Vaena, Daniel A.
    Kohli, Manish
    Crispino, Tony
    Vogelzang, Nicholas J.
    Thompson, Ian Murchie
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
    Calcagno, Fabien
    Mouillet, Guillaume
    Adotevi, Olivier
    Maurina, Tristan
    Nguyen, Thierry
    Montcuquet, Philippe
    Curtit, E.
    Kleinclauss, F.
    Pivot, Xavier
    Borg, Christophe
    Thiery-Vuillemin, Antoine
    MEDICAL ONCOLOGY, 2016, 33 (08)
  • [39] Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial
    Fabien Calcagno
    Guillaume Mouillet
    Olivier Adotevi
    Tristan Maurina
    Thierry Nguyen
    Philippe Montcuquet
    E. Curtit
    F. Kleinclauss
    Xavier Pivot
    Christophe Borg
    Antoine Thiery-Vuillemin
    Medical Oncology, 2016, 33
  • [40] LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naive prostate cancer (mHNPC)
    Feyerabend, S.
    Tran, N.
    Fein, L.
    Matsubara, N.
    Rodriguez Antolin, A.
    Alekseev, B.
    Ozguroglu, M.
    Ye, D.
    Protheroe, A.
    De Porre, P.
    Kheoh, T.
    Park, Y. C.
    Todd, M.
    Chi, K.
    Fizazi, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 113 - 113
12345